Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2026)

Akebia Therapeutics has reported EBITDA Margin over the past 9 years, most recently at 21.25% for Q4 2025.

  • Quarterly EBITDA Margin rose 2780.0% to 21.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.26% through Dec 2025, up 4107.0% year-over-year, with the annual reading at 2.26% for FY2025, 4107.0% up from the prior year.
  • EBITDA Margin was 21.25% for Q4 2025 at Akebia Therapeutics, down from 0.92% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 45.94% in Q4 2021 and troughed at 156.94% in Q2 2021.
  • The 5-year median for EBITDA Margin is 27.85% (2023), against an average of 46.27%.
  • The largest YoY upside for EBITDA Margin was 30134bps in 2021 against a maximum downside of -6438bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 45.94% in 2021, then tumbled by -124bps to 10.88% in 2022, then surged by 110bps to 1.09% in 2023, then crashed by -4589bps to 49.04% in 2024, then skyrocketed by 57bps to 21.25% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EBITDA Margin are 21.25% (Q4 2025), 0.92% (Q3 2025), and 0.4% (Q2 2025).